Altria Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MO research report →
Range $58 – $79
Price Chart
About the company
Operating across the United States through its subsidiaries, Altria Group, Inc. is a prominent manufacturer and marketer of both combustible and oral tobacco items. Its portfolio features cigarettes, primarily under the iconic Marlboro brand, alongside cigars and pipe tobacco mainly offered as Black & Mild.
- CEO
- Sal Mancuso
- IPO
- 1985
- Employees
- 5,900
- HQ
- Richmond, VA, US
AI snapshot
Six angles, distilled from the data.
MO is in a long consolidation after a strong multi-month run, but the trend has cooled from its 52-week high and now sits near its 200-day moving average. That setup points to a mature defensive name rather than a momentum breakout, with the next move likely driven by earnings and yield support.
Street sentiment is constructive but not euphoric: the consensus is Buy with a $71.33 target, above the current share price. Recent action is mixed, with UBS still positive at $79 while Barclays cut its target to $58, signaling wider disagreement on upside.
Earnings have been uneven but workable, with a 5/8 beat rate over the last eight quarters. Next-year EPS is modeled at 5.864 versus 4.7 TTM, so shareholders should watch whether pricing power and volume stability can keep that path intact after the latest 1.48 vs 1.50 miss.
Recent insider activity leans bearish on discretionary trades, with three sales and no open-market buys. The awards and vesting-related grants are noise; the signal is the selling by directors and an officer, including a 27,908-share sale by the HR/compliance chief and smaller director sales in late May.
Margins remain exceptionally strong, with a 61.46% operating margin and 39.0% net margin, while revenue still grew 1.2% year over year. Free cash flow was $9.506 billion in fiscal 2025, but leverage stays heavy at $25.709 billion of debt against $4.481 billion of cash.
MO wins on cash generation and margin profile versus most consumer staples names, but tobacco’s secular volume pressure keeps growth modest. The stock still screens as a value-and-income name, trading at 11.81x earnings, below the broader staples premium.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $112.06B
- P/E
- 14.16
- Fwd P/E
- 11.80
- PEG
- -1.67
- P/S
- 5.12
- P/B
- -42.06
- EV/EBITDA
- 11.43
- Div Yield
- 6.32%
- Gross Margin
- 70.99%
- Op Margin
- 55.95%
- Net Margin
- 36.46%
- ROE
- -265.17%
- ROIC
- 36.68%
Latest fiscal year · YoY change
- Revenue
- $20.14B-1.5%
- Gross Profit
- $14.54B+1.2%
- Op Income
- $12.04B
- Net Income
- $6.95B-38.3%
- EPS
- $4.11-37.2%
- OCF Growth
- +6.1%
- FCF Growth
- +5.4%
- 52W High
- $77.06
- 52W Low
- $54.70
- 50D MA
- $70.45
- 200D MA
- $65.74
- Beta
- 0.49
- RSI (14)
- 46
- Avg Volume
- 8.62M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Altria delivered a strong first half, narrowed full-year EPS guidance, and said smoke-free growth, stable premium cigarette pricing, and tighter illicit-product enforcement are supporting the outlook.· July 30, 2026
- Adjusted diluted EPS rose 2.8% to $1.48 in Q2 and 4.9% to $2.80 in the first half.
- Full-year 2026 adjusted EPS guidance was narrowed to $5.61-$5.72, up 3.5%-5.5% versus $5.42 in 2025.
- Smokeable products remained the main earnings driver, with adjusted OCI up 2.4% to $3.0 billion in Q2 and margin expanding to 64.8%.
- on! PLUS is scaling: 49.9 million cans shipped in Q2, retail share reached 8.6%, and national 12 mg and new flavors are planned.
- Management said cigarette volume declines are moderating, helped by tougher enforcement against illicit e-vapor products and less cross-category switching.
Altria reported adjusted diluted EPS of $1.48 in Q2, up 2.8% year over year, and $2.80 for the first half, up 4.9%. Smokeable products adjusted OCI rose 2.4% to $3.0 billion in Q2 and 4.2% to $5.7 billion in the first half, with adjusted OCI margins of 64.8% and 64.9%, respectively. Reported domestic cigarette volumes declined 3.2% in Q2 and 2.8% in the first half; when adjusted for trade inventory movements, declines were estimated at 4.5% and 4.0%. Oral Tobacco Products adjusted OCI fell 8% in Q2 and 4.2% in the first half, while ABI adjusted equity earnings rose 21.5% to $158 million. Management raised the low end of 2026 adjusted EPS guidance and now expects $5.61 to $5.72, implying 3.5% to 5.5% growth versus a 2025 base of $5.42.
Sal Mancuso said the company is executing on three priorities: advancing the smoke-free portfolio, defending profitability in traditional tobacco, and returning capital to shareholders. He highlighted on! PLUS expansion to 120,000 stores, early traction from the product, and planned line extensions later this year, while also pointing to Marlboro Cowboy Cut as a value option that fits the brand’s American heritage. His tone was confident but measured, repeatedly noting that consumers remain under economic pressure and that second-half investments will rise as the company supports launches.
Heather Newman emphasized that first-half results were strong enough to justify narrowing full-year guidance. She cited Q2 adjusted EPS of $1.48, smokeable OCI of $3.0 billion, smokeable OCI margin of 64.8%, Oral Tobacco Products OCI margin of 66.7%, and ABI adjusted equity earnings of $158 million. She also said Altria returned about $3.6 billion in dividends and repurchased 5.3 million shares for $335 million in the first half, ended Q2 with $665 million remaining under the buyback program, and had a debt-to-EBITDA ratio of 1.9x, in line with the roughly 2x target.
Analysts focused on why the second-half EPS setup is not above the strong first-half pace, with management saying timing differences, higher investment for on! PLUS extensions, and duty drawback timing explain the pattern. On cigarettes, management said volume declines are moderating because cross-category switching into illicit e-vapor appears to be slowing as enforcement improves, even as gas prices and inflation still pressure consumers. On on! PLUS, management said the brand is gaining share, the soft-pouch format is resonating, and new 12 mg and flavor extensions should support further growth, though Q2 shipments were affected by prior-year comparisons and launch timing.
The call’s bullish case is that Altria is simultaneously protecting legacy cash flows and building a smoke-free growth platform. Management pointed to on! PLUS share gains, broader distribution, stronger brand awareness, and a more constructive FDA/enforcement backdrop that could help future launches. They also highlighted resilient Marlboro premium leadership, disciplined discount participation through Basic, and continued strong shareholder returns.
The main risks discussed were continued consumer pressure, especially from inflation and high gas prices, and the possibility that second-half trends do not fully match first-half strength. Oral Tobacco Products OCI fell year over year, cigarette volumes still declined, and management acknowledged that Basic-driven discount growth and on! promotional investments could weigh on mix and near-term earnings. In vape, management still faces a prevalent illicit market and said any re-entry into the category will be disciplined and not yet timed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 1.67B
- Float Shares
- 1.67B
of shares held by institutions
2,553 13F filers
Buy/sell ratio 5.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Jan 13, 26 | Filing → |
| Sheri BiggsHouse · SC03 | Sell | Mar 19, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 4, 25 | Filing → |
| Pete SessionsHouse · TX17 | Sell | Sep 10, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Mar 20, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 13, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 10, 24 | Filing → |
| Virginia FoxxHouse · NC05 | Sell | Jan 16, 24 | Filing → |
| Virginia FoxxHouse · NC05 | Sell | Jan 10, 24 | Filing → |
| Virginia FoxxHouse · NC05 | Buy | Jan 11, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 10, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 10, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 2, 23 | Filing → |
| Virginia FoxxHouse · NC05 | Buy | Oct 11, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 160.98M | ▲ 1.90M |
| Blackrock, Inc. | 126.07M | ▲ 1.33M |
| Vanguard Capital Management LLC | 109.03M | ▲ 196.91K |
| State Street Corp | 70.19M | ▼ 1.60M |
| Charles Schwab Investment Management Inc | 59.12M | ▲ 4.84M |
| Sixth Street Partners Management Company, L.P. | 59.12M | ▲ 59.12M |
| Capital Research Global Investors | 58.65M | ▲ 32.97M |
| Geode Capital Management, LLC | 47.72M | ▲ 699.21K |
| Gqg Partners LLC | 25.11M | ▲ 1.27M |
| Morgan Stanley | 22.70M | ▼ 1.75M |
| Ameriprise Financial Inc | 22.05M | ▲ 544.33K |
| Capital World Investors | 18.48M | ▲ 64.57K |
Held by 1,261 ETFs
Biggest fund positions in MO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 26, 26 | KELLY ENNIS DEBRA J | sell | 5,790 |
| May 26, 26 | Strahlman Ellen R | sell | 2,000 |
| May 14, 26 | Strahlman Ellen R | other | 2,571 |
| May 14, 26 | Stoddart Richard S | other | 2,571 |
| May 14, 26 | Clarke Ian L.T. | other | 2,571 |
| May 14, 26 | Connelly Marjorie Mary | other | 2,571 |
| May 14, 26 | KELLY ENNIS DEBRA J | other | 2,571 |
| May 14, 26 | Davis Robert Matthews | other | 2,571 |
| May 14, 26 | SHANKS VIRGINIA E | other | 2,571 |
| May 14, 26 | YZAGUIRRE MARIO MAX | other | 2,571 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MO coverage
Recent articles, reports, and earnings notes.

Altria Group (MO): Cash Flow, Pouches, and Cigarette Decline
Altria combines strong cash generation and Marlboro pricing power with a growing on! pouch franchise, but cigarette volume declines and leverage keep the stock in Hold territory.

Altria Group, Inc. (MO) drops 8% after Q2 EPS miss
Altria Group, Inc. (MO) drops after reporting second-quarter results that missed profit expectations. Revenue edged higher, but weaker adjusted EPS and a cautious outlook pressured the stock, even as the company’s dividend yield remains attractive for income investors.
Want a deeper read on MO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
The 5% Treasury Is Exposing Every Fake Dividend Stock
247wallst.com · Aug 19
Fifth Third Bancorp Sells 10,453 Shares of Altria Group, Inc. $MO
defenseworld.net · Aug 19
Cascade Financial Partners LLC Sells 11,687 Shares of Altria Group, Inc. $MO
defenseworld.net · Aug 19
August's 5 Dividend Growth Stocks With Yields Up To 6.21%
seekingalpha.com · Aug 18
Should You Buy the 3 Highest-Yielding Dividend King Consumer Staples Stocks?
fool.com · Aug 18
Commonwealth Retirement Investments LLC Lowers Stake in Altria Group, Inc. $MO
defenseworld.net · Aug 18
Elyxium Wealth LLC Raises Holdings in Altria Group, Inc. $MO
defenseworld.net · Aug 18
HUB Investment Partners LLC Increases Stock Position in Altria Group, Inc. $MO
defenseworld.net · Aug 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed August 13, 2026 · Live quote · Not investment advice